Why These Investment Firms Bet $400 Million On A Chinese Ozempic Rival
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center.| Forbes
